Cefepime Hydrochloride/Taniborbactam
- Generic Name
- Cefepime Hydrochloride/Taniborbactam
Everest Medicines Advances mRNA Tumor Vaccine Pipeline Amidst Financial Growth
• Everest Medicines is focusing on mRNA-based therapeutic vaccines, with its first personalized mRNA tumor vaccine, EVM16, now in clinical trials.
• Nefecon, Everest's drug for IgA nephropathy, achieved substantial sales of 167 million yuan shortly after launch, highlighting its market potential.
• The company's financial performance is strong, with a 158% revenue increase in the first half of the year and expectations to achieve cash break-even by the end of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath